Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.68 |
| ▸ | MME | P08473 | 3/20 | 0.58 |
| ▸ | BACE1 | P56817 | 4/20 | 0.56 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.55 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | CPA1 | P15085 | 2/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748615 | 1.00 | NAALAD2 (0.68) | NAALAD2MMEBACE1SLC15A1BACE2 | |
| SCHEMBL29602993 | 1.00 | NAALAD2 (0.68) | NAALAD2MMEBACE1SLC15A1BACE2 | |
| SCHEMBL3732243 | 1.00 | NAALAD2 (0.68) | NAALAD2MMEBACE1SLC15A1BACE2 | |
| SCHEMBL27914476 | 1.00 | NAALAD2 (0.68) | NAALAD2MMEBACE1SLC15A1BACE2 | |
| SCHEMBL8821940 | 0.97 | NAALAD2 (0.64) | NAALAD2MMEBACE1SLC15A1BACE2 | |
| SCHEMBL29827935 | 0.96 | NAALAD2 (0.67) | NAALAD2MMEBACE1BACE2 | |
| SCHEMBL29469738 | 0.95 | NAALAD2 (0.61) | NAALAD2MMEBACE1BACE2 | |
| SCHEMBL29603574 | 0.94 | NAALAD2 (0.60) | NAALAD2MMEBACE1BACE2 | |
| Trifluoroacetic Acid SCHEMBL29617362 | 0.94 | NAALAD2 (0.60) | NAALAD2MMEBACE1SLC15A1BACE2 | |
| SCHEMBL29531169 | 0.94 | NAALAD2 (0.60) | NAALAD2MMEBACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014232-A1 | Pharmaceutical Composition of GLP-1 and GIP Receptor Dual Agonist and Use Thereof | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-01-15 | — | — | US | claimed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4659592-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | House Foods Corporation (JP) | 2025-12-10 | — | — | EP | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| WO-2025093774-A1 | GLUCAGON-LIKE PEPTIDE 1 AGONISTS | Constructive Biology Limited (GB) | 2025-05-08 | — | — | WO | claimed |
| US-20250115654-A1 | PHARMACEUTICAL COMPOSITION OF GLP-1 RECEPTOR AND GIP RECEPTOR DUAL AGONIST, AND USE THEREOF | Fujian Shengdi Pharmaceutical Co., Ltd. (CN) | 2025-04-10 | — | — | US | claimed |
| CN-119780446-A | Biomarker for milk cow early pregnancy related state and application thereof | 宁夏大学 | 2025-04-08 | — | — | CN | claimed |
| CN-118897023-B | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2025-03-25 | — | — | CN | claimed |
| CN-118897023-A | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2024-11-05 | — | — | CN | claimed |
| CN-118754965-A | GLP-1 and GIP receptor dual agonist compounds and uses thereof | 北京拓界生物医药科技有限公司 | 2024-10-11 | — | — | CN | claimed |
| EP-2546649-B1 | Biomarkers for fatty liver disease and methods using the same | METABOLON INC (US) | 2015-02-25 | — | — | EP | claimed |
| EP-2546649-A2 | Biomarkers for fatty liver disease and methods using the same | Metabolon Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| EP-2227689-B1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-20100279956-A1 | Biomarkers For Fatty Liver Disease And Methods Using The Same | METABOLON, INC. | 2010-11-04 | — | — | US | claimed |
| US-5643955-A | CARBOXYL-CONTAINING DIPEPTIDES AND DERIVATIVES (TASTANDS) TO REDUCE OR ELIMIATE A ITTER OR METALLIC TASTE; FOODS; DRUGS; ARTIFICIAL SWEETENERS; POTASSIUM CHLORIDE | BIORESEARCH, INC. (US) | 1997-07-01 | — | — | US | claimed |
| US-5631038-A | COMPOUNDS (TASTANDS) TO REDUCE OR ELIMINATE A BITTER OR METALLIC TASTE ARE ADDED TO FOODS CONTAINING SODIUM CHLORIDE | BIORESEARCH, INC. (US) | 1997-05-20 | — | — | US | claimed |
| EP-0728419-A2 | Ingestible containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers | BIORESEARCH, INC. (US) | 1996-08-28 | — | — | EP | claimed |
| EP-0661932-A4 | SPECIFIC EATABLE TASTE MODIFIERS. | BIORESEARCH INC (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0661932-A1 | SPECIFIC EATABLE TASTE MODIFIERS | BIORESEARCH, INC. (US) | 1995-07-12 | — | — | EP | claimed |
| WO-1993010677-A1 | SPECIFIC EATABLE TASTE MODIFIERS | BIORESEARCH, INC. (US) | 1993-06-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | NAALAD2 4066/4885MME 2240/4885BACE1 72/4885 |
| US-20260014232-A1 | Pharmaceutical Composition of GLP-1 and GIP Receptor Dual Agonist and Use Thereof | GLP1R, GIPR, GCGR | NAALAD2 1969/4885MME 3730/4885BACE1 1593/4885 |
| US-20250115654-A1 | PHARMACEUTICAL COMPOSITION OF GLP-1 RECEPTOR AND GIP RECEPTOR DUAL AGONIST, AND USE THEREOF | GLP1R, GIPR, GCGR | NAALAD2 2901/4885MME 1798/4885BACE1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.